Why targeted use of desiccants and scavengers matters:

Desiccants and oxygen scavengers serve as protective packaging tools to mitigate moisture and oxygen ingress. However, their use should not be default or precautionary. Instead, their inclusion must be based on actual stability study outcomes or forced degradation data indicating sensitivity to humidity or oxidation. Inappropriate use can increase cost, complicate packaging validation, and introduce regulatory scrutiny.

Risks of unjustified inclusion:

Using these components without supporting data may trigger regulatory questions, delay submissions, or result in costly post-approval changes. Overuse can also interfere with product performance (e.g., affecting moisture content or reaction kinetics) or require unnecessary label statements. Regulators expect a risk-based justification for all primary packaging decisions.

Regulatory and Technical Context:

Guidance from ICH and global regulators:

ICH Q1A(R2) and WHO TRS 1010 mandate that packaging design be justified based on data demonstrating its ability to protect the product over its intended shelf life. FDA and EMA also expect applicants to provide evidence (e.g., impurity trends, assay loss, visual changes) to support the need for moisture or oxygen protection. The justification must be clearly documented in CTD Module 3.2.P.7 (Container Closure) and 3.2.P.8.1 (Stability Summary).

Audit expectations and submission review:

During inspections or dossier evaluations, regulators may question why a desiccant or scavenger is included. If no clear correlation exists between environmental sensitivity and product degradation, the packaging may be seen as excessive or misleading. Reviewers also assess whether inclusion was supported by degradation studies or stress tests.

Best Practices and Implementation:

Use data-driven assessments to decide inclusion:

Conduct real-time and accelerated stability studies across conditions such as 25°C/60% RH, 30°C/75% RH, and 40°C/75% RH. Evaluate whether the product shows sensitivity to moisture (e.g., dissolution delay, hydrolysis, discoloration) or oxygen (e.g., peroxide growth, color fade, assay drop). If no significant degradation is observed, avoid using additional protection. Reserve desiccant or scavenger inclusion for molecules or formulations that clearly show environmental vulnerability.

Document rationale in protocols and submissions:

Clearly state in your stability protocol whether desiccants or oxygen scavengers are used during testing. If they are part of the final marketed packaging, include comparative studies showing results with and without these components. Present this data in CTD Module 3.2.P.2.5 (Development Pharmaceutics) and reference findings in the stability justification section.

If used for only certain markets (e.g., Zone IVB), define which conditions trigger their inclusion and how performance was validated.

Control and validate their performance over shelf life:

Desiccants and scavengers themselves must be evaluated over the full product shelf life. Confirm that their capacity remains effective at the end of the study and does not leach contaminants. Include compatibility studies with product formulation, container closure materials, and label adhesives. Reference vendor certificates, qualification tests, and in-house validation in packaging dossiers.

Monitor their presence during pull points and include inspection criteria in your SOPs to ensure consistent inclusion and performance in commercial batches.

Why packaging decisions must be data-driven:

Primary packaging plays a critical role in protecting a drug product from environmental factors like moisture, oxygen, and light. Choosing the right material must go beyond aesthetics or cost—it should be backed by product-specific stability data.

Aligning packaging with the product’s sensitivity ensures that efficacy, safety, and appearance remain within specifications throughout the shelf life.

Examples of product-packaging mismatches:

Moisture-sensitive tablets packaged in HDPE bottles without desiccants may fail early in Zone IVb. Photolabile formulations stored in clear blisters could degrade rapidly under light exposure.

Such mismatches often result in batch failures, label changes, recalls, or costly reformulation after commercialization.

Aligning packaging with intended use and markets:

Packaging should reflect the distribution environment and regional regulatory expectations. A formulation stable in Zone II may require reinforced packaging in Zone IVb to avoid humidity-induced degradation.

This tip ensures the package protects the product not only in the lab but also across global supply chains.

Regulatory and Technical Context:

ICH and global expectations for packaging justification:

ICH Q1A(R2) and Q5C emphasize that packaging should be justified using real-time and accelerated stability data. Agencies like the FDA, EMA, and CDSCO require this data as part of product registration dossiers.

Packaging justification must demonstrate that the selected system maintains the integrity of the drug product throughout its lifecycle.

Container-closure integrity testing (CCIT):

In addition to stability data, regulatory bodies expect supportive evidence from CCIT or extractable/leachable studies. These ensure that the closure system prevents ingress of air, moisture, or contaminants.

CCIT is especially important for injectables, hygroscopic formulations, or temperature-sensitive biologics.

Linking packaging to labeling and claims:

Stability outcomes directly influence storage claims like “Protect from light” or “Store below 25°C.” These must be aligned with packaging features, such as UV-protective materials or barrier foils.

Discrepancies between data and labeling may trigger regulatory queries or post-approval commitments.

Best Practices and Implementation:

Perform packaging simulation during stability studies:

Stability studies should use the final intended market pack, not just bulk containers or interim formats. Simulated transport and distribution studies also validate packaging under real-world conditions.

Track any visual or functional changes in the package alongside product degradation metrics to ensure system integrity.

Include comparative studies where needed:

If multiple packaging options exist (e.g., blister vs. bottle), conduct head-to-head studies. This helps justify packaging changes post-approval or respond to supply chain disruptions with data-backed flexibility.

Document observations like moisture uptake, visual changes, or assay drift to support packaging decisions with evidence.

Integrate packaging review into formulation lifecycle:

Don’t treat packaging as an afterthought—review and revalidate it at key stages such as formulation changes, line transfers, or regulatory submissions in new regions.

Update SOPs to include packaging verification checkpoints during each stability protocol approval cycle.